The introduction of new drugs invites clinical investigation as to their therapeutic efficacy. This report is based on clinical findings resulting from the sole or supportive treatment of selected dermatoses with tetracycline hydrochloride (Tetracyn*). This drug1 is a derivative from chlortetracyline in which the chlorine atom is replaced by a hydrogen atom. This new compound has pharmacologic properties similar to its parent drug but appears to be more soluble and stable. It has been found that tetracycline can be tolerated at higher levels than chlortetracycline or oxytetracycline. It produces a minimum of side-reactions such as nausea, vomiting, and diarrhea. Its antibacterial activity is almost identical to that of its analogues and it is readily diffused throughout the body after oral administration.
The present report is a clinical study which was started April 1, 1954, and was concluded Sept. 30 of the same year
GOLDBERG LC. TREATMENT OF PYOGENIC DERMATOSES WITH TETRACYCLINE HYDROCHLORIDE. AMA Arch Derm. 1955;71(5):638–639. doi:10.1001/archderm.1955.01540290078021
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: